Actinium Pharmaceuticals Inc (ATNM)

1.72
AMEX : Health Care
Prev Close 1.72
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.52 / 3.50
Avg Volume 307.10K
Exchange AMEX
Shares Outstanding 46.95M
Market Cap 83.10M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of September 18th Options Trading For Actinium Pharmaceuticals (ATNM)

First Week Of September 18th Options Trading For Actinium Pharmaceuticals (ATNM)

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the September 18th expiration.

Interesting ATNM Put Options For February 2016

Interesting ATNM Put Options For February 2016

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2016 expiration.

Short Interest Increases 18% For ATNM

Short Interest Increases 18% For ATNM

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, which shows a 387,097 share increase in total short interest for Actinium Pharmaceuticals, Inc. , to 2,526,804, an increase of 18.09% since 04/30/2015.

Interesting ATNM Put And Call Options For November 20th

Interesting ATNM Put And Call Options For November 20th

Investors in Actinium Pharmaceuticals, Inc. saw new options begin trading this week, for the November 20th expiration.

Actinium Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

Actinium Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock

Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the...

3 Biotech Stocks Under $10 in Breakout Territory

3 Biotech Stocks Under $10 in Breakout Territory

Keep these under-$10 biotech stocks on your breakout trading radar.

5 Breakout Stocks Under $10 Set to Soar Higher

5 Breakout Stocks Under $10 Set to Soar Higher

These stocks trading for less than $10 a share are within range of triggering breakout trades.

MD Anderson Department Chair Richard E. Champlin, M.D. Joins Actinium’s Iomab™-B Scientific Advisory Board

MD Anderson Department Chair Richard E. Champlin, M.D. Joins Actinium’s Iomab™-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Actinium Files Orphan Drug Application For Use Of Actimab-A In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Elderly Patients

Actinium Files Orphan Drug Application For Use Of Actimab-A In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Elderly Patients

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Actinium To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10th

Actinium To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10th

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Actinium To Present At The Canaccord Genuity 34th Annual Growth Conference On August 13th

Actinium To Present At The Canaccord Genuity 34th Annual Growth Conference On August 13th

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Actinium Pharmaceuticals Provides Mid-Year Update Directed At Existing And Future Shareholders

Actinium Pharmaceuticals Provides Mid-Year Update Directed At Existing And Future Shareholders

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today provided...

Baylor Sammons Cancer Center Joins As Clinical Trial Site For Actinium’s Actimab-A Clinical Trial

Baylor Sammons Cancer Center Joins As Clinical Trial Site For Actinium’s Actimab-A Clinical Trial

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program

CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program

Headline of release should read: Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program (instead of Actinium Pharmaceuticals, Inc.

Oversold Conditions For Actinium Pharmaceuticals (ATNM)

Oversold Conditions For Actinium Pharmaceuticals (ATNM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Actinium Announces Exercise Of Greenshoe Option

Actinium Announces Exercise Of Greenshoe Option

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Baylor Oncology Medical Director Joins Actinium’s Iomab-B Scientific Advisory Board

Baylor Oncology Medical Director Joins Actinium’s Iomab-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Actinium Joins Russell 3000®, Russell 2000®, Russell Global, And Russell Micro-Cap® Indexes

Actinium Joins Russell 3000®, Russell 2000®, Russell Global, And Russell Micro-Cap® Indexes

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, joined the ...

Actinium Closes Public Offering Of Common Shares

Actinium Closes Public Offering Of Common Shares

Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Preeminent Oncology Clinicians from Leading Cancer Centers Join Actinum’s Newly Established Iomab-B Scientific Advisory Board

Preeminent Oncology Clinicians from Leading Cancer Centers Join Actinum’s Newly Established Iomab-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today ...

Actinium Prices $12.5 Million Public Offering Of Common Shares

Actinium Prices $12.5 Million Public Offering Of Common Shares

Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Actinium Announces Proposed Public Offering Of Common Shares

Actinium Announces Proposed Public Offering Of Common Shares

Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...

Actinium’s Actimab-A And Alpha-Particle Immunotherapy Platform Further Validated At Society For Nuclear Medicine Annual Meeting

Actinium’s Actimab-A And Alpha-Particle Immunotherapy Platform Further Validated At Society For Nuclear Medicine Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, provided ...

Actinium To Present At The 2014 BIO International Convention In San Diego On June 26th

Actinium To Present At The 2014 BIO International Convention In San Diego On June 26th

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced...